Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Modern Endoscopic Imaging in Diagnosis and Surveillance of Inflammatory Bowel Disease Patients

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The Effect of a Synthetic Heparan Sulfate on the Healing of Colonic Anastomoses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exercise training and the progression of chronic renal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Svein Oskar Frigstad
  • Anne Haaber
  • Antal Bajor
  • Jan Fallingborg
  • Per Hammarlund
  • Ole K Bonderup
  • Håkan Blom
  • Terje Rannem
  • Per M Hellström
Vis graf over relationer

Background: Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract.

Objective: The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside.

Methods: A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year.

Results: Out of 282 patients, 82 had Crohn's disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients.

Conclusion: Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction. This trial is registered with NCT01900197.

TidsskriftGastroenterology Research and Practice
Sider (fra-til)4585164
StatusUdgivet - 2017

ID: 52743778